Compare SLP & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLP | ARMP |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 320.9M | 295.5M |
| IPO Year | 1996 | 1996 |
| Metric | SLP | ARMP |
|---|---|---|
| Price | $15.28 | $8.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $24.00 | $15.00 |
| AVG Volume (30 Days) | ★ 268.0K | 72.3K |
| Earning Date | 04-09-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $59,577,000.00 | N/A |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $58.31 | ★ N/A |
| Revenue Growth | ★ 10.52 | N/A |
| 52 Week Low | $11.09 | $1.74 |
| 52 Week High | $34.01 | $14.98 |
| Indicator | SLP | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 41.76 |
| Support Level | $13.95 | $5.14 |
| Resistance Level | $15.59 | $12.11 |
| Average True Range (ATR) | 1.07 | 1.08 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 51.14 | 31.90 |
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.